A method is proposed for estimating the overall absorption kinetics of drugs (expressed as percent of total amount absorbed versus time) from plasma data. It is applicable to the study of drugs whose kinetics can be described by linear one- or two-compartment models. Use is made of an iterative process based on the differential equations of the model and on linear interpolation of plasma data. The method does not require that the overall absorption kinetics should be apparent first-order and/or that the model parameters should be estimated from a previous experiment. It was tested for the influence of data scatter: added noise (CV = 10%) resulted in a variability of percent absorbed versus time of the same order of magnitude. During the calculations, the microscopic rate constants are estimated and optimalized. Data scatter resulted in wide variations in the estimates of the two-compartment model parameters. However, when a sufficiently large number of plasma concentration-time curves were studied, an average model could be determined with a reasonable precision. Model kinetics calculated from the related parameter estimates were in agreement with the theory. The method permits the exploitation of the various plasma concentration-time curves which are available after the development of an orally administered drug.
A method for the quantitative determinatio of 1,2,3-propanetrioltrinitrate (nitroglycerin) in human plasma by gas chromatography mass spectrometry has been developed. After addition of 1,2,3 and methyl acetate (90 : 10). The extracts are purified by partition between, first, the extraction solvent and a mixture of acetonitrile and water (60 : 40) and, secondly, the resultant aqueous phase and benzene. THe solvent is evaporated to a small volume before injection. The fragment ions at m/z 46 and 47 are monitored for the measurement of the [NO2]+ and [15NO2]+ ions using electron impact ionization. The mean recovery (%) +/- SD in blind plasma samples spiked with amounts in the concentration range 0.35-3.52 nmol 1(-1), was 97.4 +/- 9.0 (n = 58). Within a day, recovery experiments gave rise to coefficients of variation of 9.6, 6.4 and 2.7% at the levels 0.44, 0.88 and 11 nmol 1(-1), respectively. Concentrations in plasma down to about 0.2 nmol 1(-1) (50 pg ml-1) could be estimated. Percent recovery of duplicate determinations in the range 0.5-1.96 nmol 1(-1) +/- SD was 99.4 +/- 6.0 (n = 80).
Negative ionization resulted in the simplification of a previously published method. The new method permits the determination of 0.25 nmol l-1 nitroglycerol in plasma with a coefficient of variation of 9.1%.
A gas chromatographic/mass spectrometric method for the specific determination of oxprenolol and 2H6-labelled oxprenolol when both are present in the same sample is described. After addition of 13C3-labelled oxprenolol as internal standard, plasma is alkalized and extracted by a mixture of dichloromethane and diethyl ether. The residue following evaporation of the organic phase is derivatized with heptafluorobutyric anhydride. Negative ion detection with N2O as reagent gas is used for the measurements at m/z 488, 491 and 494 for oxprenolol, the 13C3-labelled internal standard and 2H6-labelled oxprenolol, respectively. The precision and accuracy of the analytical method were investigated using samples containing both unlabelled and 2H6-labelled oxprenolol. The overall mean recovery (% +/- SD, n = 70) in the concentration range 20-1500 nmol l-1 (around 6-450 ng ml-1 of the hydrochloride salts) was 100.6 +/- 3.3 and 101.0 +/- 3.5 for oxprenolol and 2H6-labelled oxprenolol, respectively. The limit of quantification was around 20 nmol l-1 for both compounds.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.